/PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for.
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company s Psychedelic Digital Therapeutics Technology Platform
News provided by
Share this article
Share this article
Utilizing Speak Ai s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
VANCOUVER, BC, April 13, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. ( Speak Ai ). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform s capabilities into iSTRYM, and will also work with Speak Ai to develop prop
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
News provided by
Share this article
Share this article
An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth companies
VANCOUVER, BC, March 15, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company s new Chief Operating Officer, effective immediately. Mr. Lebbadi steps in to assume the role previously held by President & CEO Kelsey Ramsden. He is an accomplished international executive and operator with extensive experience in healthcare and technology, having served in a leadership position at Johnson & Johnson and at several high-growth technology companies. Most recently, he served in a strategic operational capacity at Aurora Cannab
/PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for.
his potential treatment opportunity was confirmed by the company s bioinformatics platform, PsyCollage
VANCOUVER, BC, March 4, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company s bioinformatics platform,
PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma.
Ibogaine is a psychoactive substance extracted from the iboga shrub native to West Africa. Contributing to its powerful anti-addiction actions, ibogaine is associated with increases in the levels of brain neurotrophic factors, particularly GDNF and BDNF, which have potent neuroregenerative and neuroprotective properties.